Evidence map›Paper›PMID 38844623›Full record

ArticleArchives of dermatological research2024

Predictors for the use of systemic therapy in stage IB Mycosis fungoides.

Elijah Rodriguez, Carli D Needle, Michael J Martinez, Ambika Nohria, Yiping Xing, Clara Song, Rebecca Betensky, Jo-Ann Latkowski, Prince Adotama

Erratum issuedAbstract readMulticenter StudyLetter
PubMed Publisher
In one paragraph

Article in Archives of dermatological research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Elijah RodriguezThe Ronald O. Perelman Department of Dermatology, New York University Grossman School of Medicine, 240 East 38th Street, Floor 11, New York, NY, 10016, USA.
Carli D NeedleThe Ronald O. Perelman Department of Dermatology, New York University Grossman School of Medicine, 240 East 38th Street, Floor 11, New York, NY, 10016, USA.
Michael J MartinezThe Ronald O. Perelman Department of Dermatology, New York University Grossman School of Medicine, 240 East 38th Street, Floor 11, New York, NY, 10016, USA.
Ambika NohriaThe Ronald O. Perelman Department of Dermatology, New York University Grossman School of Medicine, 240 East 38th Street, Floor 11, New York, NY, 10016, USA.
Yiping XingHackensack University Medical Center, Hackensack, NJ, USA.
Clara SongDepartment of Biostatistics, New York University School of Global Public Health, New York, NY, USA.
Rebecca BetenskyDepartment of Biostatistics, New York University School of Global Public Health, New York, NY, USA.
Jo-Ann LatkowskiThe Ronald O. Perelman Department of Dermatology, New York University Grossman School of Medicine, 240 East 38th Street, Floor 11, New York, NY, 10016, USA.
Prince AdotamaThe Ronald O. Perelman Department of Dermatology, New York University Grossman School of Medicine, 240 East 38th Street, Floor 11, New York, NY, 10016, USA. prince.adotama@nyulangone.org.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study is aprospective analysis of an international database. Here we examine front-line treatments and quality of life (QoL) inpatients with newly diagnosed mycosis fungoides (MF).

objectivesTo identify (i) differences in first-line approaches according to tumour-nodes-metastasis-blood (TNMB)staging; (ii) parameters related to a first-line systemic approach and (iii) response rates and QoL measures.

methodsIn total, 395 newly diagnosed patients with early-stage MF (stage IA-IIA) were recruited from 41 centresin 17 countries between 1 January 2015 and 31 December 2018 following central clinicopathological review.

resultsThe most common first-line therapy was skin-directed therapy (SDT) (322 cases, 81·5%), while a smallerpercentage (44 cases, 11·1%) received systemic therapy. Expectant observation was used in 7·3%. In univariateanalysis, the use of systemic therapy was significantly associated with higher clinical stage (IA, 6%; IB, 14%; IIA,20%; IA-IB vs. IIA, P < 0·001), presence of plaques (T1a/T2a, 5%; T1b/T2b, 17%; P < 0·001), higher modified Severity Weighted Assessment Tool (> 10, 15%; ≤ 10, 7%; P = 0·01) and folliculotropic MF (FMF) (24% vs. 12%, P = 0·001). Multivariate analysis demonstrated significant associations with the presence of plaques (T1b/T2b vs.T1a/T2a, odds ratio 3·07) and FMF (odds ratio 2·83). The overall response rate (ORR) to first-line SDT was 73%,while the ORR to first-line systemic treatments was lower (57%) (P = 0·027). Health-related QoL improvedsignificantly both in patients with responsive disease and in those with stable disease.

conclusionsDisease characteristics such as presence of plaques and FMF influence physician treatment choices,and SDT was superior to systemic therapy even in patients with such disease characteristics. Consequently, futuretreatment guidelines for early-stage MF need to address these issues.

Indexed as

Mycosis FungoidesNeoplasm StagingQuality of LifeSkin NeoplasmsAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedPrognosisProspective StudiesTreatment OutcomeCutaneous T cell lymphomaMycosis fungoidesPhototherapySystemic therapy

Identifiers

PMID38844623

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.